Health Care & Life Sciences » Pharmaceuticals | Instituto Rosenbusch

Instituto Rosenbusch S.A. | Income Statement

Fiscal year is January-December. All values ARS Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
85,185.40
107,662.60
135,492.90
167,306.00
172,138.40
298,918.70
Cost of Goods Sold (COGS) incl. D&A
57,532.40
75,676.20
98,760.50
107,467.40
115,883.30
218,461.70
Gross Income
27,653.00
31,986.40
36,732.50
59,838.60
56,255.20
80,457
SG&A Expense
22,977.10
28,429.10
38,867.00
45,635.10
57,082.50
81,258.30
EBIT
4,675.90
3,073.60
2,134.50
14,203.50
827.30
1,574.10
Unusual Expense
-
-
35.00
2,273.50
1,910.50
836.20
Non Operating Income/Expense
8,501.60
11,574.70
11,036.80
9,179.30
12,563.00
40,940.30
Interest Expense
2,845.90
4,452.50
7,252.40
7,866.70
5,374.00
17,829.50
Pretax Income
6,602.70
10,195.70
1,614.90
13,242.70
4,451.20
20,700.50
Income Tax
1,709.00
458.50
576.60
1,584.90
2,538.90
11,145.40
Consolidated Net Income
8,311.60
9,737.30
1,038.30
11,657.80
1,912.30
9,555.10
Net Income
9,120.30
8,346.20
727.50
10,162.70
72.30
798.30
Net Income After Extraordinaries
9,120.30
8,346.20
727.50
10,162.70
72.30
798.30
Net Income Available to Common
9,120.30
8,346.20
727.50
10,162.70
72.30
798.30
EPS (Basic)
0.21
0.20
0.02
0.24
0.00
0.02
Basic Shares Outstanding
42,371.90
42,589.50
42,589.50
42,589.50
42,589.50
42,589.50
EPS (Diluted)
0.22
0.20
0.02
0.24
0.00
0.02
Diluted Shares Outstanding
42,371.90
42,589.50
42,589.50
42,589.50
42,589.50
42,589.50
EBITDA
7,276.40
5,645.50
627.50
17,865.30
3,271.50
8,613.20
Other Operating Expense
-
483.70
-
-
-
772.90
Non-Operating Interest Income
69.00
-
-
-
-
-
Minority Interest Expense
808.70
1,391.00
1,765.80
1,495.10
1,984.60
8,756.90

About Instituto Rosenbusch

View Profile
Address
HipĆ³lito Yrigoyen 1628
Buenos Aires Buenos Aires 1089
Argentina
Employees -
Website http://www.rosenbusch.com
Updated 07/08/2019
Instituto Rosenbusch SA engages in the manufacture and marketing of veterinary products. It operates through the following business segments: Biological Products, Pharmaceutical Products, and Others. The Biological Products segment includes products for reproductive-respiratory complex, brucellosis and carbuncle, clostridial and other vaccines, horses, pneumonia and calve diarrhea, and queratoconjuntivitis.